Cited 17 times in
Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 용동은 | - |
dc.contributor.author | 이경원 | - |
dc.contributor.author | 정석훈 | - |
dc.contributor.author | 정윤섭 | - |
dc.date.accessioned | 2015-12-28T11:02:00Z | - |
dc.date.available | 2015-12-28T11:02:00Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2234-3806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138548 | - |
dc.description.abstract | BACKGROUND: Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea. METHODS: A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method. RESULTS: Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline were 2-4 µg/mL and 8-16 µg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole. CONCLUSIONS: Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | ANNALS OF LABORATORY MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Anti-Infective Agents/pharmacology* | - |
dc.subject.MESH | Bacteroides Infections/microbiology* | - |
dc.subject.MESH | Bacteroides Infections/pathology | - |
dc.subject.MESH | Bacteroides fragilis/drug effects* | - |
dc.subject.MESH | Bacteroides fragilis/isolation & purification | - |
dc.subject.MESH | Drug Resistance, Multiple, Bacterial | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imipenem/pharmacology | - |
dc.subject.MESH | Inhibitory Concentration 50 | - |
dc.subject.MESH | Microbial Sensitivity Tests | - |
dc.subject.MESH | Penicillanic Acid/analogs & derivatives | - |
dc.subject.MESH | Penicillanic Acid/pharmacology | - |
dc.subject.MESH | Piperacillin/pharmacology | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.subject.MESH | Thienamycins/pharmacology | - |
dc.title | Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Laboratory Medicine (진단검사의학) | - |
dc.contributor.googleauthor | Jisook Yim | - |
dc.contributor.googleauthor | Yangsoon Lee | - |
dc.contributor.googleauthor | Myungsook Kim | - |
dc.contributor.googleauthor | Young Hee Seo | - |
dc.contributor.googleauthor | Wan Hee Kim | - |
dc.contributor.googleauthor | Dongeun Yong | - |
dc.contributor.googleauthor | Seok Hoon Jeong | - |
dc.contributor.googleauthor | Kyungwon Lee | - |
dc.contributor.googleauthor | Yunsop Chong | - |
dc.identifier.doi | 10.3343/alm.2015.35.1.94 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02423 | - |
dc.contributor.localId | A02649 | - |
dc.contributor.localId | A03619 | - |
dc.contributor.localId | A03679 | - |
dc.relation.journalcode | J00164 | - |
dc.identifier.eissn | 2234-3814 | - |
dc.identifier.pmid | 25553287 | - |
dc.subject.keyword | Antimicrobial resistance | - |
dc.subject.keyword | Bacteroides fragilis group | - |
dc.subject.keyword | Moxifloxacin | - |
dc.subject.keyword | Tigecycline | - |
dc.contributor.alternativeName | Yong, Dong Eun | - |
dc.contributor.alternativeName | Lee, Kyung Won | - |
dc.contributor.alternativeName | Jeong, Seok Hoon | - |
dc.contributor.alternativeName | Chong, Yun Sop | - |
dc.contributor.affiliatedAuthor | Yong, Dong Eun | - |
dc.contributor.affiliatedAuthor | Lee, Kyung Won | - |
dc.contributor.affiliatedAuthor | Jeong, Seok Hoon | - |
dc.contributor.affiliatedAuthor | Chong, Yun Sop | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 94 | - |
dc.citation.endPage | 98 | - |
dc.identifier.bibliographicCitation | ANNALS OF LABORATORY MEDICINE, Vol.35(1) : 94-98, 2015 | - |
dc.identifier.rimsid | 38375 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.